Affordable Access

[Phase II study of VP-16 (capsule) in solid tumors. A cooperative study].

Authors
  • Honma, T
  • Ogawa, M
  • Yoshida, S
  • Meguro, S
  • Hirano, M
  • Hoshino, A
  • Shirakawa, S
  • Nakamura, T
  • Fukuoka, M
  • Toki, H
Type
Published Article
Journal
Gan to kagaku ryoho. Cancer & chemotherapy
Publication Date
Feb 01, 1985
Volume
12
Issue
2
Pages
309–313
Identifiers
PMID: 2982332
Source
Medline
License
Unknown

Abstract

A phase II study of VP-16, a semisynthetic Podophyllotoxin, was performed in patients with solid tumors. VP-16 was administered orally at a dose of 200mg/day for 5 consecutive days at 3 to 4-week intervals. Out of 41 patients who were entered into the study, 35 patients comprising 17 lung cancer, 10 hepatoma and 8 other tumors were evaluable. There were 4 partial responses (23.5%) for lung cancer, 1 (10.0%) for hepatoma and 1 for rhabdomyosarcoma. Overall response rate was 18.2% for patients with prior chemotherapy and 15.4% for those given no prior chemotherapy respectively. Thus the results indicated VP-16 has no cross-resistance to other antitumor agents. Leukopenia (less than 4,000/mm3) and thrombocytopenia (less than 10 X 10(4)/mm3) were observed in 72.7% and 29.4% of the patients, respectively. Other toxicities were alopecia (59.5%) and gastrointestinal disturbances such as nausea (46.2%), vomiting (20.5%) and anorexia (20.5%), but these were all well tolerated.

Report this publication

Statistics

Seen <100 times